妊娠期亚临床甲状腺功能减退症与低甲状腺素血症产后进展为明显甲状腺功能减退症:两项随机对照试验数据的汇总分析
本汇总分析基于两项多中心随机对照试验中安慰剂组孕妇,比较妊娠8-20周诊断的亚临床甲状腺功能减退症(SH)与低甲状腺素血症(HT)产后1年和5年明显甲状腺功能减退症的发生率。SH组产后1年(13.4% vs 3.1%,p<0.001)和5年(15.6% vs 2.6%,p<0.001)发生率均高于HT组。SH组基线TPO抗体>50 IU/mL者产后1年和5年发生率均更高。
要点
- SH孕妇产后1年和5年明显甲减发生率均高于HT孕妇。
- SH组基线TPO>50 IU/mL者产后1年和5年甲减风险更高(OR分别为5.3和5.4)。
- TSH>10 mIU/mL者进展为明显甲减更常见。
核心结论
- 妊娠前半期诊断的SH与产后5年内明显甲状腺功能减退症或甲状腺替代治疗发生率高于HT相关。
研究设计与样本
- 两项多中心治疗试验的二次分析,纳入妊娠8-20周诊断的SH或HT并随机分配至安慰剂组的个体。
- SH诊断标准为TSH≥4.0 mU/L且游离T4正常(0.86-1.9 ng/dL),HT诊断标准为TSH正常(0.08-3.99 mU/L)但游离T4<0.86 ng/dL。
- 产后1年和5年随访时询问是否诊断或治疗甲状腺疾病并采集母体血清检测甲状腺功能。
- 后续明显甲减定义为TSH≥4.0 mU/L且游离T4<0.86 ng/dL。
- SH组338例中307例、HT组261例中229例有产后1年和5年随访数据。
主要发现
- SH组产后1年明显甲减发生率为13.4%,HT组为3.1%(p<0.001)。
- SH组产后5年明显甲减发生率为15.6%,HT组为2.6%(p<0.001)。
- TSH>10 mIU/mL者进展为明显甲减更常见。
关键数值与推荐
- SH诊断:TSH≥4.0 mU/L且游离T4正常(0.86-1.9 ng/dL)。
- HT诊断:TSH正常(0.08-3.99 mU/L)但游离T4<0.86 ng/dL。
- 明显甲减定义:TSH≥4.0 mU/L且游离T4<0.86 ng/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: To examine the incidence of overt hypothyroidism 1 and 5 years after pregnancies where screening before 21 weeks identified subclinical hypothyroidism (SH) or hypothyroxinemia (HT). Methods: Secondary analysis of two multicenter treatment trials for either SH or HT diagnosed between 8 and 20 weeks gestation. Current analyses focus only on individuals randomized to the placebo groups in the two parallel studies. SH was diagnosed with thyrotropin (TSH) ≥4.0 mU/L and normal free T4 (fT4) (0.86-1.9 ng/dL). HT was diagnosed with normal TSH (0.08-3.99 mU/L) but fT4 <0.86 ng/dL. Serum from initial testing was stored for later thyroid peroxidase (TPO) antibody assay; results were not returned for clinical management. At 1 and 5 years after delivery, participants were asked whether they had either been diagnosed with or were being treated for a thyroid condition. Maternal serum was collected at these visits and thyroid function measured. Subsequent overt hypothyroidism was defined as TSH ≥4.0 mU/L with fT4 <0.86 ng/dL. Results: Data for 1- and 5-year follow-up were available in 307 of the 338 participants with SH and 229 of the 261 with HT. Subsequent hypothyroidism was more common both at year 1 (13.4% vs. 3.1%, p < 0.001) and year 5 (15.6% vs. 2.6%, p < 0.001) for participants with SH compared with those with HT. This progression was more common in individuals with TSH values >10 mIU/mL. Baseline TPO level >50 IU/mL in participants with SH was associated with higher rates of hypothyroidism at year 1 (26.7% vs. 6.5%, odds ratio [OR] = 5.3 [confidence interval (CI) 2.6-10.7]) and year 5 (30.5% vs. 7.5%, OR = 5.4 [CI: 2.8-10.6]) compared with those with TPO levels ≤50 IU/mL. For participants with HT, no differences in overt hypothyroidism were seen at 1 year related to baseline TPO level >50 IU/mL (1/10 (10%) vs. 6/218 (2.8%), OR = 3.9 [CI: 0.43-36.1]), but more participants with TPO levels >50 IU/mL developed hypothyroidism by year 5 (2/10 (20%) vs. 4/218 (1.8%), OR = 13.4 [CI: 2.1-84.1]). Conclusion: SH is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years of delivery than is HT when these conditions are diagnosed in the first half of pregnancy.
引用
- Varner MW, Mele L, Casey BM, et al. Progression of Gestational Subclinical Hypothyroidism and Hypothyroxinemia to Overt Hypothyroidism After Pregnancy: Pooled Analysis of Data from Two Randomized Controlled Trials. Thyroid. 2024. PMID: 39028022. doi:10.1089/thy.2023.0616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。